Potential drug interactions in cancer therapy: A prevalence study using an advanced screening method

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2334-2341

  van Leeuwen, R W F ^a,b   Swart, E L ^a   Boven, E ^a   Boom, F A ^b   Schuitenmaker, M G ^b   Hugtenburg, J G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ZAANS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Drug interactions; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CENTRAL DEPRESSANT AGENT; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; COUMARIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; LEVOFLOXACIN; METHOTREXATE; MITOXANTRONE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PREDNISOLONE; QUINOLONE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN UPTAKE INHIBITOR; SOTALOL; TAMOXIFEN; UNINDEXED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SCREENING; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DEPRESSION; COMORBIDITY; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERICUM PERFORATUM; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT CODING; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RISK FACTOR;

EID: 80053137998     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq761     Document Type: Article

References (48)

1. Kohler GI, Bode-Boger SM, Busse R et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504-513.
2. Buajordet I, Ebbesen J, Erikssen J et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327-341.
3. Riechelmann RP, Tannock IF, Wang L et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600.
4. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006; 6: 546-558.
5. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004; 5: 489-496.
6. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-778.
7. Geppert U, Beindl W, Hawranek T, Hintner H. Drug interactions in clinical practice. A pilot project for quality assurance in prescribing. Hautarzt 2003; 54: 53-57.
8. Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 2005; 61: 675-681.
9. Goldberg RM, Mabee JPAC, Chan L et al. Drug-drug and drug disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14: 447-450.
10. Riechelmann RP, Moreira F, Smaletz O et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005; 56: 286-290.
11. Tascilar M, De Jong FA, Verweij J, Mathijssen RHJ. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006; 11: 732-741.
12. Wolters Kluwer Health. Drug Interaction Facts. Version 4.0. 2006; http://www.factsandcomparisons.com (16 February 2011, date last accessed).
13. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004; 61: 380-385.
14. Mathijssen RHJ, Verweij J, De Bruijn P et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-1249.
15. Scientific Advisory Board of the Arizona Center for Education and Research on Therapeutics. QT drug lists. http://www.arizonacert.org (16 February 2011, date last accessed).
16. Schimmel KJ, Richel DJ, van den Brink RB et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-191.
17. Camidge R, Reigner B, Cassidy J et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005; 23: 4719-4725.
18. Kinikar SA, Kolesar JM. Identification of a gemcitabine-warfarin interaction. Pharmacotherapy 1999; 19: 1331-1333.
19. Le AT, Hasson NK, Lum BL. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 1997; 31: 1006-1008.
20. Couderc LJ, Stelianides S, Frachon I et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. Respir Med 1999; 93: 65-68.
21. Lafforgue P, Monjanel-Mouterde S, Durand A et al. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol 1993; 20: 263-267.
22. Tracy TS, Krohn K, Jones DR et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42: 121-125.
23. Johnson EJ, MacGowana AP, Potterb MN et al. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother 1990; 25: 837-842.
24. Kolesar JM, Johnson CL, Freeberg BL et al. Warfarin-5-FU interaction-a consecutive case series. Pharmacotherapy 1999; 19: 1445-1449.
25. Tashima CK. Cyclophosphamide effect on coumarin anticoagulation. South Med J 1979; 72: 633-634.
26. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin. Ann Oncol 2003; 14: 500.
27. Orr LE. Potentiation of myelosuppression from cancer chemotherapy and thiazide diuretics. Drug Intell Clin Pharm 1981; 15: 967-970.
28. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 1989; 87: 505-510.
29. De Jonge ME, Huitema AD, Van Dam SM et al. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 2005; 55: 507-510.
30. Ikeda H, Murakami T, Takano M. Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient. Br J Clin Pharmacol 2005; 59: 593-597.
31. Stolbach L, Begg C, Bennett JM et al. Evaluation of bone marrow toxic reaction in patients treated with allopurinol. JAMA 1982; 247: 334-336.
32. Mainwaring P, Grygiel JJ. Interaction of 5-fluorouracil with folates. Aust N Z J Med 1995; 25: 60.
33. Piper JM, Ray WA, Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-740.
34. Official Package Labeling for Emend (Aprepitant). Whitehouse Station, NJ: Merck and Co. Inc. 2008.
35. Official Package Labeling for Actiq (Fentanyl Citrate). Salt Lake City, UT: Cephalon Inc. 2007.
36. Fisher AA, Davis MW. Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. Ann Pharmacother 2002; 36: 67-71.
37. Depré M, Van Hecken A, Oeyen M et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005; 61: 341-346.
38. Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 2006; 40: 2101-2106.
39. Van der Linden PD, Sturkenboom MC, Herings RM. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med 2003; 163: 1801-1807.
40. Legler UF. Lack of impairment of fluocortolone disposition in oral contraceptive users. Eur J Clin Pharmacol 1988; 35: 101-103.
41. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med 2003; 348: 42-49.
42. Hartikainen S, Mantyselka P, Louhivuori-Laako K et al. Concomitant use of analgesics and psychotropics in home-dwelling elderly people-Kuopio 75+ study. Br J Clin Pharmacol 2005; 60: 306-310.
43. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47: 30-39.
44. Woolcott JC, Richardson KJ, Wiens MO et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169: 1952-1960.
45. Lord SR, Menz HB, Tiedemann A. A physiological profile approach to falls risk assessment and prevention. Phys Ther 2003; 83: 237-252.
46. Gralow JR, Biermann JS, Farooki A et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 2009; 7 (Suppl 3): S1-S32.
47. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998: 93: 2037.
48. Singh G, Rosen Ramey D. NSAID-induced gastrointestinal complications: the ARAMIS perspective-1997. J Rheumatol 1998; 25 (Suppl 51): 8-16.